MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. Co. develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. We show 6 historical shares outstanding datapoints in our MLTX shares outstanding history coverage, used to compute MLTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MLTX market cap history over the course of time is important for investors
interested in comparing MLTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MLTX versus a peer is one thing; comparing
MLTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MLTX can fluctuate over the course of history.
With this page we aim to empower investors researching MLTX by allowing them to research the MLTX market cap history. |
Free MLTX Email Alerts:
Video: The Importance of Market Cap
